Study of Doravirine/Islatravir (DOR/ISL 100 mg/0.75 mg) to Evaluate the Antiretroviral Activity, Safety, and Tolerability in Treatment-Naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-020)
Clinical trial NCT04233879 · COMPLETED
Trial details
- NCT number
- NCT04233879
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-02-28
- Primary completion
- 2022-11-17
- Enrollment
- 599
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.